Shore Capital Reiterates Buy Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “buy” rating reaffirmed by investment analysts at Shore Capital in a research report issued on Wednesday, Marketbeat.com reports.

Separately, JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research report on Friday, March 28th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat, GSK has an average rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($23.99).

GSK Stock Performance

Shares of GSK opened at GBX 1,463 ($19.44) on Wednesday. The company’s 50 day simple moving average is GBX 1,432.77 and its 200-day simple moving average is GBX 1,400.52. GSK has a 12-month low of GBX 1,242.50 ($16.51) and a 12-month high of GBX 1,823.50 ($24.23). The firm has a market cap of £59.37 billion, a PE ratio of 23.63, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last released its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities analysts predict that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling at GSK

In other news, insider Wendy Becker bought 536 shares of the business’s stock in a transaction that occurred on Thursday, March 20th. The shares were acquired at an average cost of GBX 1,515 ($20.13) per share, with a total value of £8,120.40 ($10,788.36). Also, insider Emma Walmsley sold 120,653 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of GBX 1,453 ($19.30), for a total value of £1,753,088.09 ($2,329,066.15). 1.61% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.